目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Stage Type
1.1.3 Customer Type
1.1.4 Therapeutic Area
1.1.5 Regional Scope
1.1.6 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.5.1 Approaches Used To Estimate The Market Size
1.5.1.1 Approach 1: Region-Wise Market Estimation Using Bottom-Up Approach
1.5.1.2 Approach 2: Parent Market Analysis
1.5.1.3 Approach 3: Commodity Flow (Company Share Analysis)
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 OBJECTIVE - 1:
1.9.2 OBJECTIVE - 2:
1.9.3 OBJECTIVE - 3:
1.9.4 OBJECTIVE - 4:

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook

Chapter 3 Small Molecule Innovators CDMO Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Demand for Small Molecule Drug
3.2.1.2 Growing Demand for Small Molecules in the Oncology Segment
3.2.1.3 Increasing Pharmaceutical R&D Investments
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent Government Regulations
3.3.2.2 Compliance Issues with Outsourcing
3.3 Small Molecule Innovators CDMO Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.4 Impact of COVID-19 and Reformation Strategies

Chapter 4 Small Molecule Innovator CDMO Market: Product Segment Analysis
4.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
4.2 Small Molecule API
4.2.1 Small Molecule API, 2018 - 2030 (USD Million)
4.3 Small Molecule Drug Product
4.3.1 Small Molecule Drug Product Market, 2018 - 2030 (USD Billion)
4.3.2 Oral Solid Dose
4.3.2.1 Oral Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.3 Semi-Solid Dose
4.3.3.1 Semi-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.4 Liquid Dose
4.3.4.1 Liquid-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.5 Others
4.3.5.1 Others Market, 2018 - 2030 (USD Billion)

Chapter 5 Small Molecule Innovators CDMO Market: Stage Type Segment Analysis
5.1 Small Molecule Innovators Cdmo: Market Share Analysis, 2022 & 2030
5.2 Preclinical
5.2.1 Preclinical Market, 2018 - 2030 (USD Billion)
5.3 Clinical
5.3.1 Clinical Market, 2018 - 2030 (USD Billion)
5.3.2 Phase I
5.3.2.1 Phase I Market, 2018 - 2030 (USD Billion)
5.3.2.2 Small
5.3.2.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.2.3 Medium
5.3.2.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.2.4 Large
5.3.2.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.3 Phase II
5.3.3.1 Phase II Market, 2018 - 2030 (USD Billion)
5.3.3.2 Small
5.3.3.2.1. Small Market, 2018 - 2030 (USD Billion)
5.3.3.3 Medium
5.3.3.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.3.4 Large
5.3.3.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.4 Phase III
5.3.4.1 Phase III Market, 2018 - 2030 (USD Billion)
5.3.4.2 Small
5.3.4.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.4.3 Medium
5.3.4.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.4.4 Large
5.3.4.4.1. Large Market, 2018 - 2030 (USD Billion)
5.4 Commercial
5.4.1. Commercial Market, 2018 - 2030 (USD Billion)

Chapter 6 Small Molecule Innovators CDMO Market: Customer Type Segment Analysis
6.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
6.2 Pharmaceutical
6.2.1 Pharmaceutical Market, 2018 - 2030 (USD Million)
6.2.2 Small
6.2.2.1 Small Market, 2018 - 2030 (USD Million)
6.2.3 Medium
6.2.3.1 Medium Market, 2018 - 2030 (USD Million)
6.2.4 Large
6.2.4.1 Large Market, 2018 - 2030 (USD Million)
6.3 Biotechnology
6.3.1 Biotechnology Market, 2018 - 2030 (USD Million)

Chapter 7 Small Molecule Innovators CDMO Market: Therapeutic Area Segment Analysis
7.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
7.2 Cardiovascular Disease
7.2.1 Cardiovascular diseases market, 2018 - 2030 (USD Million)
7.3 Oncology
7.3.1 Oncology market, 2018 - 2030 (USD Million)
7.4 Respiratory Disorders
7.4.1 Respiratory disorders market, 2018 - 2030 (USD Million)
7.5 Neurology
7.5.1 Neurology market, 2018 - 2030 (USD Million)
7.6 Metabolic Disorders
7.6.1 Metabolic disorders market, 2018 - 2030 (USD Million)
7.7 Infectious Diseases
7.7.1 Infectious diseases market, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Others market, 2018 - 2030 (USD Million)

Chapter 8 Small Molecule Innovators CDMO Market: Regional Analysis
8.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
8.2 North America
8.2.1 North America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.2 U.K.
8.3.2.1 U.K. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.3 Germany
8.3.3.1 Germany Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 France Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Italy Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Spain Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Denmark Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Sweden Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.9 Norway
8.3.9.1 Norway Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.2 India
8.4.2.1 India Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.3 Japan
8.4.3.1 Japan Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.4 China
8.4.4.1 China Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.5 Australia
8.4.5.1 Australia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.6 South Korea
8.4.6.1 South Korea Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.7 Thailand
8.4.7.1 Thailand Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6 MEA
8.6.1 MEA Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.4 UAE
8.6.4.1 UAE Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.5 Kuwait
8.6.5.1 Kuwait Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape
9.1 Company Profiles
9.1.1 Lonza
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Service benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Patheon (Thermo Fisher Scientific)
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Service benchmarking
9.1.2.4 Strategic initiatives
9.1.3 Cambrex Corporation
9.1.3.1 Company overview
9.1.3.2 Service benchmarking
9.1.3.3 Strategic initiatives
9.1.4 Catalent, Inc
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Service benchmarking
9.1.5 Siegfried Holding AG
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Service benchmarking
9.1.5.4 Strategic initiatives
9.1.6 Recipharm AB
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Service benchmarking
9.1.6.4 Strategic initiatives
9.1.7 CordenPharma International
9.1.7.1 Company overview
9.1.7.2 Service benchmarking
9.1.7.3 Strategic initiatives
9.1.8 Boehringer ingelheim
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Service benchmarking
9.1.8.4 Strategic initiatives
9.1.9 Piramal Pharma Solutions
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Service benchmarking
9.1.9.4 Strategic initiatives
9.1.10 Labcorp Drug Development
9.1.10.1 Company overview
9.1.10.2 Financial performance
9.1.10.3 Service benchmarking
9.1.10.4 Strategic initiatives
9.2 Company Analysis
9.2.1 Heat Map Analysis of Competitors

List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Small Molecule Innovators CDMO market snapshot (2020) (USD Million)
Fig. 9 Small Molecule Innovator market segmentation
Fig. 10 Parent market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Small Molecule Innovator CDMO market Product outlook: Segment dashboard
Fig. 17 Small Molecule Innovators CDMO market: Product movement analysis
Fig. 18 Small Molecule API market 2018 - 2030 (USD Million)
Fig. 19 Small Molecule Drug Product Market, 2018 - 2030 (USD Million)
Fig. 20 Oral solid dose Market, 2018 - 2030 (USD Million)
Fig. 21 Semi-solid Dose Market, 2018 - 2030 (USD Million)
Fig. 22 Semi-Solid Dose Market, 2018 - 2030 (USD Million)
Fig. 23 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 24 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 25 Small Molecule Innovators CDMO market: Stage type movement analysis
Fig. 26 Preclinical market, 2018 - 2030 (USD Million)
Fig. 27 Clinical market, 2018 - 2030 (USD Million)
Fig. 28 Phase I market, 2018 - 2030 (USD Million)
Fig. 29 Small market, 2018 - 2030 (USD Million)
Fig. 30 Medium market, 2018 - 2030 (USD Million)
Fig. 31 Large market, 2018 - 2030 (USD Million)
Fig. 32 Phase II market, 2018 - 2030 (USD Million)
Fig. 33 Small market, 2018 - 2030 (USD Million)
Fig. 34 Medium market, 2018 - 2030 (USD Million)
Fig. 35 Large market, 2018 - 2030 (USD Million)
Fig. 36 Phase III market, 2018 - 2030 (USD Million)
Fig. 37 Small market, 2018 - 2030 (USD Million)
Fig. 38 Medium market, 2018 - 2030 (USD Million)
Fig. 39 Large market, 2018 - 2030 (USD Million)
Fig. 40 Commercial market, 2018 - 2030 (USD Million)
Fig. 41 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 42 Small Molecule Innovators CDMO market: Customer type movement analysis
Fig. 43 Pharmaceutical market, 2018- 2030 (USD Million)
Fig. 44 Small market, 2018 - 2030 (USD Million)
Fig. 45 Medium market, 2018 - 2030 (USD Million)
Fig. 46 Large market, 2018 - 2030 (USD Million)
Fig. 47 Biotechnology market, 2018 - 2030 (USD Million)
Fig. 48 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 49 Small Molecule Innovators CDMO market: Therapeutic area movement analysis
Fig. 50 Cardiovascular Disease market, 2018 - 2030 (USD Million)
Fig. 51 Oncology market, 2018 - 2030 (USD Million)
Fig. 52 Respiratory Disorders market, 2018 - 2030 (USD Million)
Fig. 53 Neurology market, 2018 - 2030 (USD Million)
Fig. 54 Metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 55 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 56 Other’s market, 2018 - 2030 (USD Million)
Fig. 57 Regional market: Key takeaways
Fig. 58 Small Molecule Innovators CDMO market: Regional movement analysis
Fig. 59 North America market, 2018 - 2030 (USD Million)
Fig. 60 U.S. market, 2018 - 2030 (USD Million)
Fig. 61 Canada market, 2018 - 2030 (USD Million)
Fig. 62 Europe market, 2018 - 2030 (USD Million)
Fig. 63 U.K. market, 2018 - 2030 (USD Million)
Fig. 64 Germany market, 2018 - 2030 (USD Million)
Fig. 65 France market, 2018 - 2030 (USD Million)
Fig. 66 Italy market, 2018 - 2030 (USD Million)
Fig. 67 Spain market, 2018 - 2030 (USD Million)
Fig. 68 Denmark market, 2018 - 2030 (USD Million)
Fig. 69 Sweden market, 2018 - 2030 (USD Million)
Fig. 70 Norway market, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 73 India market, 2018 - 2030 (USD Million)
Fig. 74 Japan market, 2018 - 2030 (USD Million)
Fig. 75 China market, 2018 - 2030 (USD Million)
Fig. 76 Australia market, 2018 - 2030 (USD Million)
Fig. 77 South Korea market, 2018 - 2030 (USD Million)
Fig. 78 Thailand market, 2018 - 2030 (USD Million)
Fig. 79 Latin America market, 2018 - 2030 (USD Million)
Fig. 80 Brazil market, 2018 - 2030 (USD Million)
Fig. 81 Mexico market, 2018 - 2030 (USD Million)
Fig. 82 Argentina market, 2018 - 2030 (USD Million)
Fig. 83 MEA market, 2018 - 2030 (USD Million)
Fig. 84 South Africa market, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 86 UAE market, 2018 - 2030 (USD Million)
Fig. 87 Kuwait market, 2018 - 2030 (USD Million)
Fig. 88 Heat Map Analysis